AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3890538 — intervention group
Group type: COMPARATOR
Intervention: gentamicin and clindamycin
Number of subjects: 74
Study 29793353 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 150
Study 29793353 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 150
Study 30048547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (OF) 7g twice daily
Number of subjects: 37
Study 30048547 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin (MD) 7g twice daily
Number of subjects: 37
Study 30048547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 37
Study 27235528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobi-C implant
Number of subjects: 99
Study 27235528 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 99
Study 24793409 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental impedance spectroscopy with combined multiple electrodes added to the 15 lead ECG
Number of subjects: 119
Study 24793409 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental impedance spectroscopy
Number of subjects: 119
Study 23406605 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable hyaluronan hydrogel
Number of subjects: 55
Study 23406605 — intervention group
Group type: COMPARATOR
Intervention: Control (no absorbable hyaluronan hydrogel)
Number of subjects: 55
Study 20653437 — intervention group
Group type: EXPERIMENTAL
Intervention: Early healing (14 weeks)
Number of subjects: 33
Study 20653437 — intervention group
Group type: COMPARATOR
Intervention: Delayed healing (27 weeks)
Number of subjects: 33
Study 18959605 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 4385
Study 18959605 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 4385
Study 15992789 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA therapy
Number of subjects: 35
Study 15992789 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 35
Study 15992789 — intervention group
Group type: COMPARATOR
Intervention: Non-therapy patients
Number of subjects: 35
Study 15992789 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study 12847783 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI-2
Number of subjects: 0
Study 12847783 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI
Number of subjects: 0
Study 10231223 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (N‐acetylcysteine, selenium, vitamins C and E) for 7 days
Number of subjects: 18
Study 10231223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant therapy)
Number of subjects: 18
Study 8897027 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise protocol (cycling for three periods of 6 min at power outputs of 55%, 70%, and 85% VO2max)
Number of subjects: 64
Study 8897027 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise protocol
Number of subjects: 64
Study 1986895 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLW‐SI (Single Indicator)
Number of subjects: 18
Study 1986895 — intervention group
Group type: COMPARATOR
Intervention: EVLW‐DI (Double Indicator)
Number of subjects: 18
Study 1986895 — intervention group
Group type: EXPERIMENTAL
Intervention: COfem‐si (Single Indicator Cardiac Output)
Number of subjects: 18
Study 1986895 — intervention group
Group type: COMPARATOR
Intervention: COfem‐di (Double Indicator Cardiac Output)
Number of subjects: 18
Study 6363154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimazine (sulfadiazine 900 mg + trimethoprim 300 mg)
Number of subjects: 30
Study 6363154 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 g daily
Number of subjects: 30
Study 31193330 — intervention group
Group type: EXPERIMENTAL
Intervention: HVGIC/CHX
Number of subjects: 100
Study 31193330 — intervention group
Group type: COMPARATOR
Intervention: HVGIC
Number of subjects: 100
Study 30369351 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM) intervention
Number of subjects: 40
Study 30369351 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 40
Study 27266229 — intervention group
Group type: EXPERIMENTAL
Intervention: Plai cream (n = 70 patients)
Number of subjects: 140
Study 27266229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 70 patients)
Number of subjects: 140
Study 25208616 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group treated with specific techniques added to conventional physiotherapy for stroke
Number of subjects: 13
Study 25208616 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with conventional physiotherapy for stroke
Number of subjects: 13
Study 23088168 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist management alone
Number of subjects: 300
Study 23088168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist management plus HP support
Number of subjects: 300
Study 22874106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two 510 mg i.v. injections within 5 ± 3 days)
Number of subjects: 608
Study 22874106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 608
Study 22874106 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 608
Study 16201069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (270mg/day before each meal for 20 weeks)
Number of subjects: 10
Study 16201069 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 10
Study 12598441 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID ophthalmic solution (bromfenac sodium hydrate) co-administered twice daily for 2 weeks
Number of subjects: 13
Study 12598441 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost ophthalmic solution administered once daily
Number of subjects: 13
Study 12598441 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of bromfenac sodium hydrate ophthalmic solution
Number of subjects: 13
Study 12598441 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-administration of bromfenac sodium ophthalmic solution
Number of subjects: 13
Study 10378127 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 78
Study 8655705 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of abnormal expression of CD44 gene products in exfoliated cells from patients with colorectal carcinoma.
Number of subjects: 27
Study 8655705 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of retention of intron 9 in CD44 mRNA transcripts in washings from carcinoma specimens.
Number of subjects: 27
Study 8655705 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of solid tissue samples from patients with colorectal carcinoma.
Number of subjects: 27
Study 8655705 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of low level expression of CD44 exons in tissue from inflammatory lesions.
Number of subjects: 27
Study 1856922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored and valved (modified) ileal ureter
Number of subjects: 50
Study 1856922 — intervention group
Group type: COMPARATOR
Intervention: Standard operation
Number of subjects: 50
Study 6347277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily for 1 year)
Number of subjects: 720
Study 6347277 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 720
Study 6347277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 720
Study 6347277 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen and No further therapy (both)
Number of subjects: 720
Study 6347277 — intervention group
Group type: EXPERIMENTAL
Intervention: PgR negative patients
Number of subjects: 720
Study 30475959 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein group (>0.80 g · kg‐1 · d‐1)
Number of subjects: 729
Study 30475959 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein group (≤0.80 g · kg‐1 · d‐1)
Number of subjects: 729
Study 30475959 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein group
Number of subjects: 729
Study 30475959 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein group
Number of subjects: 729
Study 28816912 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-part distance-learning, quality improvement intervention (web-based education, collaborative consultation with ADHD experts, performance feedback reports/calls)
Number of subjects: 105
Study 28816912 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 105
Study 26654738 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB)
Number of subjects: 31
Study 26654738 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution (RLS)
Number of subjects: 31
Study 24050808 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery care
Number of subjects: 1748
Study 24050808 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 1748
Study 21935814 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg, 2 capsules of 5 mg each)
Number of subjects: 30
Study 21935814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules)
Number of subjects: 30
Study 18174769 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning hypertension (MEdif >/=15 mm Hg, MEave >/=135 mm Hg)
Number of subjects: 611
Study 18174769 — intervention group
Group type: COMPARATOR
Intervention: Well-controlled blood pressure (MEdif <15 mm Hg, MEave <135 mm Hg)
Number of subjects: 611
Study 17186724 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianggan Capsule combined with Lamivudine
Number of subjects: 85
Study 17186724 — intervention group
Group type: COMPARATOR
Intervention: Qianggan Capsule alone
Number of subjects: 85
Study 17186724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (QC and Lamivudine, QC alone)
Number of subjects: 85
Study 12811626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate (ICE)
Number of subjects: 94
Study 12811626 — intervention group
Group type: EXPERIMENTAL
Intervention: Total DPD by HPLC
Number of subjects: 94
Study 12811626 — intervention group
Group type: EXPERIMENTAL
Intervention: Free DPD by ELISA
Number of subjects: 94
Study 12811626 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 10875616 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120 vaccines
Number of subjects: 296
Study 10875616 — intervention group
Group type: COMPARATOR
Intervention: SF-2/gp120
Number of subjects: 296
Study 8864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 0.5 mg, 1 mg, or 4 mg
Number of subjects: 10
Study 8864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 10
Study 8864325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg with alcohol (0.6 mg kg‐1)
Number of subjects: 10
Study 8864325 — intervention group
Group type: COMPARATOR
Intervention: Placebo with alcohol (0.6 mg kg‐1)
Number of subjects: 10
Study 1497132 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine+buprenorphine (0.3 mg)
Number of subjects: 80
Study 1497132 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine (without buprenorphine)
Number of subjects: 80
Study 1497132 — intervention group
Group type: COMPARATOR
Intervention: control group (untreated parturients)
Number of subjects: 80
Study 1497132 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine (with or without buprenorphine)
Number of subjects: 80
Study 6407433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate derivatives
Number of subjects: 0
Study 6407433 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium inhibitors
Number of subjects: 0
Study 6407433 — intervention group
Group type: COMPARATOR
Intervention: Betablockers
Number of subjects: 0
Study 6407433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31790015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitemporal tDCS (anodal stimulation over the temporal cortices, 2 mA for 20 minutes)
Number of subjects: 17
Study 31790015 — intervention group
Group type: COMPARATOR
Intervention: Bifrontal tDCS (anodal stimulation over the dorsolateral prefrontal cortices, 2 mA for 20 minutes)
Number of subjects: 17
Study 31790015 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study 30236904 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based biofeedback therapy (20 min self-training sessions twice per day using a self-inserted probe for visual feedback)
Number of subjects: 100
Study 30236904 — intervention group
Group type: COMPARATOR
Intervention: Office-based biofeedback therapy (therapist-guided pelvic floor training for six sessions over 3 months)
Number of subjects: 100
Study 26611663 — intervention group
Group type: EXPERIMENTAL
Intervention: Teens.Connect (Internet psychoeducational program)
Number of subjects: 124
Study 26611663 — intervention group
Group type: COMPARATOR
Intervention: Planet D (open-access diabetes website)
Number of subjects: 124
Study 24691901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 675 mg
Number of subjects: 56
Study 24691901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 2700 mg
Number of subjects: 56
Study 24691901 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 56
Study 24691901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22421463 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (maltodextrin solution)
Number of subjects: 24
Study 21250571 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental polishing kit (EXL-695)
Number of subjects: 24
Study 21250571 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhance‐Pogo polishing kit
Number of subjects: 24
Study 21250571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐Lex polishing kit
Number of subjects: 24
Study 21250571 — intervention group
Group type: EXPERIMENTAL
Intervention: Astropol polishing kit
Number of subjects: 24
Study 21250571 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 17543894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 182
Study 17543894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 15919688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded dialyzer
Number of subjects: 7
Study 15919688 — intervention group
Group type: COMPARATOR
Intervention: Non-vitamin E-bonded dialyzer
Number of subjects: 7
Study 12133656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 598
Study 12133656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 598
Study 10425048 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA image cytometry
Number of subjects: 54
Study 10425048 — intervention group
Group type: COMPARATOR
Intervention: Control cells (lymphocytes and neutrophilic granulocytes)
Number of subjects: 54
Study 7758234 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms subcutaneous injections, 3 injections over one day)
Number of subjects: 10
Study 7758234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (octreotide vehicle, 3 injections over one day)
Number of subjects: 10
Study 7758234 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 10
Study 2271804 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous stimulus
Number of subjects: 39
Study 2271804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt crying
Number of subjects: 39
Study 2271804 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of weeping
Number of subjects: 39
Study 2271804 — intervention group
Group type: COMPARATOR
Intervention: Sad stimulus
Number of subjects: 39
Study 6163281 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate 600 mg daily
Number of subjects: 56
Study 6163281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30782701 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 hours CIMT + full-time cast
Number of subjects: 135
Study 30782701 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 hours CIMT + part-time splint
Number of subjects: 135
Study 30782701 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours CIMT + full-time cast
Number of subjects: 135
Study 30782701 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours CIMT + part-time splint
Number of subjects: 135
Study 30782701 — intervention group
Group type: COMPARATOR
Intervention: Usual and Customary Treatment (UCT)
Number of subjects: 135
Study 28087133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1470
Study 28087133 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 1470
Study 25480678 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroCoil Embolic System (HES)
Number of subjects: 96
Study 25480678 — intervention group
Group type: COMPARATOR
Intervention: Bare platinum coils (BPC)
Number of subjects: 96
Study 24049109 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg dmLT
Number of subjects: 36
Study 24049109 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg dmLT
Number of subjects: 36
Study 24049109 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg dmLT
Number of subjects: 36
Study 24049109 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg dmLT
Number of subjects: 36
Study 20606594 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE
Number of subjects: 208
Study 20606594 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 208
Study 19667281 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz at 600 mg/day plus stavudine‐lamivudine
Number of subjects: 71
Study 17561956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 185
Study 17561956 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release carbamazepine (CBZ)
Number of subjects: 185
Study 15333258 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary-derived Metrodin-HP
Number of subjects: 5
Study 15333258 — intervention group
Group type: COMPARATOR
Intervention: Recombinant-derived Gonal F
Number of subjects: 5
Study 11488378 — intervention group
Group type: EXPERIMENTAL
Intervention: leaky, competing accumulator model
Number of subjects: 0
Study 10911490 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg) daily
Number of subjects: 25
Study 10911490 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg) every 3 days
Number of subjects: 25
Study 8907211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study 8907211 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement
Number of subjects: 0
Study 1975819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 138
Study 1975819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 364260 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of acetylsalicylic acid
Number of subjects: 12
Study 364260 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (placebo)
Number of subjects: 12
Study 31511290 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based online intervention for physical activity (10-week program delivered through a private Facebook group, including education on PA and diet, and provision of an activity tracker (Fitbit)).
Number of subjects: 100
Study 27294812 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation therapy
Number of subjects: 0
Study 25907712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program (resistance, endurance, and balance training) for 12 weeks, 1 hour per day, 3 days per week
Number of subjects: 29
Study 25907712 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 23649091 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 0
Study 23649091 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A homozygosity
Number of subjects: 0
Study 23649091 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQA1 homozygosity
Number of subjects: 0
Study 23649091 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQB1 homozygosity
Number of subjects: 0
Study 23649091 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygosity at ≥ 4 HLA loci
Number of subjects: 0
Study 21499123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose IFN‐α-2a treatment
Number of subjects: 850
Study 20082927 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate diet-induced weight loss
Number of subjects: 60
Study 20082927 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight regain
Number of subjects: 60
Study 16723584 — intervention group
Group type: EXPERIMENTAL
Intervention: Brecanavir (BCV) 300 mg coadministered with 100 mg ritonavir (RTV)
Number of subjects: 0
Study 16723584 — intervention group
Group type: COMPARATOR
Intervention: Brecanavir (BCV) without RTV
Number of subjects: 0
Study 16723584 — intervention group
Group type: EXPERIMENTAL
Intervention: Brecanavir (BCV) (doses ranging from 25 mg to 800 mg)
Number of subjects: 0
Study 16723584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12837664 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-HAART
Number of subjects: 93
Study 12837664 — intervention group
Group type: COMPARATOR
Intervention: PI-naive
Number of subjects: 93
Study 12837664 — intervention group
Group type: COMPARATOR
Intervention: HIV-seronegative controls
Number of subjects: 93
Study 10571715 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCPR guidelines with additional education, spirometry, and carbon monoxide measurements
Number of subjects: 205
Study 10571715 — intervention group
Group type: COMPARATOR
Intervention: AHCPR guidelines without additional education
Number of subjects: 205
Study 10571715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 205
Study 10571715 — intervention group
Group type: COMPARATOR
Intervention: Historical data
Number of subjects: 205